A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

NCT06544616 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: JNJ-64042056
DRUG: Placebo

Sponsor

Janssen Pharmaceutica N.V., Belgium